Biocryst Pharmaceuticals (BCRX) Retained Earnings (2010 - 2026)

Biocryst Pharmaceuticals' Retained Earnings history runs 17 years deep, the most recent figure standing at -$2.2 billion for Q1 2026.

• Quarterly Retained Earnings fell 25.87% year-over-year to -$2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 billion (down 25.87% YoY) and the FY2025 annual result came in at $38000.0, up 100.0% from the prior year.
• Retained Earnings was -$2.2 billion for Q1 2026 at Biocryst Pharmaceuticals, down from $38000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $1.3 billion in Q3 2024 and bottomed at -$2.2 billion in Q1 2026.
• A 5-year average of -$872.1 million and a median of -$1.5 billion in 2023 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings soared 654203.95% — and 2023, when it tumbled 810827.42%.
• Biocryst Pharmaceuticals' Retained Earnings stood at $1.2 billion in 2022, then plunged by 245.16% to -$1.7 billion in 2023, then retreated by 5.29% to -$1.8 billion in 2024, then jumped by 100.0% to $38000.0 in 2025, then sank by 5863234.21% to -$2.2 billion in 2026.
• Business Quant data shows BCRX's Retained Earnings at -$2.2 billion in Q1 2026, $38000.0 in Q4 2025, and -$1.8 billion in Q3 2025.